42 results
425
EQRX
EQRx, Inc.
23 Oct 23
Business combination disclosure
6:13am
investigators at the Triple and ESMO meetings.
Our company’s mission is to revolutionize treatment for patients with RAS-addicted cancers through
DEFM14A
EQRX
EQRx, Inc.
29 Sep 23
Proxy related to merger
4:38pm
medicines to patients at radically lower prices (this entity is referred to as Legacy EQRx). Legacy EQRx’s mission was to improve health for all
425
EQRX
EQRx, Inc.
1 Aug 23
Business combination disclosure
5:13pm
of our mission by continuing the impressive focus, ingenuity, quality and collaboration that distinguish our remarkable organization.
Sincerely,
Mark
425
EQRX
EQRx, Inc.
1 Aug 23
Business combination disclosure
5:11pm
to 6% discount) RVMD to continue focus on mission to discover, develop and deliver pioneering RAS(ON) Inhibitor drugs on behalf of patients with RAS
425
EQRX
EQRx, Inc.
1 Aug 23
Business combination disclosure
4:29pm
with our mission to make a meaningful impact for patients and our duty to deliver value for shareholders.
We believe Revolution Medicines represents … to advance our mission of bringing innovative medicines to patients worldwide.
What Happens Next
We’ll be hosting a town hall meeting at 1 pm ET today
424B3
d0gaoo7ac4v2eo5q712
10 Nov 22
Prospectus supplement
7:24pm
DEF 14A
vajpii8n212i2tga9zwf
12 Aug 22
Definitive proxy
4:05pm
424B3
n7pzlb8r 0560w1
11 Aug 22
Prospectus supplement
9:21pm
424B3
4cp61
13 May 22
Prospectus supplement
5:24pm
POS AM
7mj4efc
23 Mar 22
Prospectus update (post-effective amendment)
6:30pm
10-K
yogc fvwh9m7otai
23 Mar 22
Annual report
4:43pm
8-K
EX-99.1
0xckchl8p9b4b
23 Mar 22
EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
7:10am
8-K
EX-99.2
8glkjd4aga
23 Mar 22
EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
7:10am
424B3
mp1 pln9no
23 Dec 21
Prospectus supplement
5:24pm
8-K
hq2a3
20 Dec 21
Entry into a Material Definitive Agreement
5:18pm